ANI Pharmaceuticals (BSFA) Stock Overview
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BSFA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ANI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.00 |
| 52 Week High | US$76.50 |
| 52 Week Low | US$68.50 |
| Beta | 0.45 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -5.13% |
| 3 Year Change | 37.04% |
| 5 Year Change | 184.62% |
| Change since IPO | 1,377.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| BSFA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -1.8% |
| 1Y | -5.1% | 39.7% | 4.2% |
Return vs Industry: BSFA underperformed the German Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: BSFA underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| BSFA volatility | |
|---|---|
| BSFA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BSFA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine BSFA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 970 | Nikhil Lalwani | www.anipharmaceuticals.com |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
ANI Pharmaceuticals, Inc. Fundamentals Summary
| BSFA fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | €85.89m |
| Revenue (TTM) | €843.75m |
Is BSFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSFA income statement (TTM) | |
|---|---|
| Revenue | US$978.38m |
| Cost of Revenue | US$387.40m |
| Gross Profit | US$590.98m |
| Other Expenses | US$491.38m |
| Earnings | US$99.60m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.65 |
| Gross Margin | 60.40% |
| Net Profit Margin | 10.18% |
| Debt/Equity Ratio | 102.2% |
How did BSFA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 22:24 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ANI Pharmaceuticals, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | Canaccord Genuity |
| Dewey Steadman | Canaccord Genuity |